The Madrid hospitals Rey Juan Carlos, Clínico San Carlos, Gregorio Marañón, La Princesa and Doce de Octubre, in addition to the Jiménez Díaz Foundation, are participating in a prospective, multicenter study led by Dr. Jesús Romero from the Puerta de Hierro University Hospital.
Tectum SkinCare is a line of treatment that helps prepare, protect and repair the skin and mucous membranes of cancer patients. Developed based on a biotechnological patent resulting from medical research by the Higher Council for Scientific Research, Tectum Skincare products are aimed at addressing the mechanisms responsible for the appearance of radiodermatitis and other skin alterations due to cancer treatments.
With the aim of delving into its mechanism of action in specific conditions, Adventia Pharma has launched a prospective, multicenter study, led by Dr. Romero from the Puerta de Hierro University Hospital in Majadahonda, to specifically study the efficacy and tolerance of Tectum Skincare in the prevention and reduction of epithelitis and mucositis in patients treated with radio or chemo-radiotherapy for head and neck cancer.
Covering a large patient population, the main hospitals in the Autonomous Community of Madrid participate in this study, which began recruiting patients in May 2019.
During the radiotherapy period, patients are treated with both Tectum Skincare facial as with colutorio, continuously assessing the appearance of epithelitis and mucositis. One of the most interesting aspects of the study is to evaluate the quality of life of these patients, using specific validated forms, during their treatment and after its completion. The added objective is thus to provide specialists with specific data that show how the proper treatment of the skin and mucous membranes in these patients with Tectum Skincare has a significant and positive impact on their quality of life.